F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment
July 12, 2017
(New York Times) – A Food and Drug Administration panel opened a new era in medicine on Wednesday, unanimously recommending that the agency approve the first-ever treatment that genetically alters a patient’s own cells to fight leukemia, transforming them into what scientists call “a living drug” that powerfully bolsters the immune system to shut down the disease. If the F.D.A. accepts the recommendation, which is likely, the treatment will be the first gene therapy ever to reach the market.